The acquisition adds rapid flow cytometry capabilities to bioMérieux’s pharmaceutical quality control portfolio, with results delivered in under 30 minutes.
France-based bioMérieux has acquired Accellix, a US company that develops rapid, automated flow cytometry solutions for cell and gene therapy quality control, for approximately $38 million.
The acquisition strengthens bioMérieux’s pharmaceutical quality control division and expands its capabilities in the advanced therapy market. Accellix’s compact flow cytometry platform delivers results in under 30 minutes, enabling real-time quality control during cell therapy manufacturing.
“Advanced therapies, including cell and gene therapies, are redefining the future of healthcare by delivering innovative, targeted solutions for patients with complex conditions. Their promise is immense, but their success depends on uncompromising quality standards,” says Yasha Mitrotti, executive vice president of industrial applications at bioMérieux, in a release. “With this acquisition, we complete our offer for cell and gene therapies by building on what we already provide for sterility, mycoplasma and endotoxin testing, as well as environmental control, now adding cell purity and viability.”
Existing Partnership Expands
bioMérieux has been collaborating with Accellix since 2020, serving shared customers in the cell and gene therapy segment. bioMérieux became the exclusive distributor of Accellix products in the Asia-Pacific region and globally for some cell and gene therapy companies.
Accellix employs approximately 70 people across locations in San José, California, and Jerusalem, Israel. The company’s platform is designed to simplify complex workflows and reduce turnaround time.
“Accellix teams’ mission is to transform the status quo for quality control and blood characterization in the cell therapy and blood collection industries, helping bring life-saving treatments to patients faster than ever before,” says Greg Hamilton, chief executive officer of Accellix, in a release. “Joining bioMérieux is a powerful catalyst for growth: It will allow us to scale our technology and impact more patients’ therapy by ensuring faster, more reliable quality control processes.”
Market Growth Drivers
Cell and gene therapies use living cells or genetic modification to repair, replace, or restore function in diseased tissues. Recent analyses show these therapies achieve clinical success rates two to three times higher than traditional treatments once they enter development.
The acquisition allows bioMérieux to test raw material and in-process quality as well as product efficacy and safety in advanced therapies. The company will support industry demand for scalable, automated quality control tools as the market continues to expand.
ID 213642156 © Kts | Dreamstime.com
